J. Flechtner

发表

T(H)17-based vaccine design for prevention of Streptococcus pneumoniae colonization.

Todd M. Gierahn, T. Gierahn, R. Malley, 2011, Cell host & microbe.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

An Adjuvanted Herpes Simplex Virus 2 Subunit Vaccine Elicits a T Cell Response in Mice and Is an Effective Therapeutic Vaccine in Guinea Pigs

D. Long, D. Bernstein, R. Cardin, 2013, Journal of Virology.

Immune responses elicited by the GEN-003 candidate HSV-2 therapeutic vaccine in a randomized controlled dose-ranging phase 1/2a trial.

D. Long, S. Hetherington, M. Škoberne, 2016, Vaccine.

Lymphocyte Immune Responses T + and Heat Shock Protein 70 Augment CD8 High-Affinity Interactions between Peptides

P. Slusarewicz, S. Andjelic, D. Levey, 2006 .

High-Affinity Interactions between Peptides and Heat Shock Protein 70 Augment CD8+ T Lymphocyte Immune Responses

P. Slusarewicz, S. Andjelic, D. Levey, 2006, The Journal of Immunology.

This information is current as Lymphocyte Immune Responses T + and Heat Shock Protein 70 Augment CD 8 High-Affinity Interactions between Peptides

P. Slusarewicz, S. Andjelic, D. Levey, 2006 .

Distinct Effects on Diversifying Selection by Two Mechanisms of Immunity against Streptococcus pneumoniae

Todd M. Gierahn, M. Lipsitch, T. Gierahn, 2012, PLoS pathogens.

The ATLAS™ screening assay reveals distinct CD4+ and CD8+ SARS-CoV-2 antigen response profiles which have implications to Omicron cellular immunity

James J Foti, Sudhir Rao, J. Flechtner, 2022, bioRxiv.

Resolution of Chlamydia trachomatis Infection Is Associated with a Distinct T Cell Response Profile

Todd M. Gierahn, T. Gierahn, J. Bodmer, 2015, Clinical and Vaccine Immunology.

Toll-Like Receptor 2-Dependent Protection against Pneumococcal Carriage by Immunization with Lipidated Pneumococcal Proteins

Todd M. Gierahn, T. Gierahn, R. Malley, 2014, Infection and Immunity.

High-throughput proteomic screening identifies Chlamydia trachomatis antigens that are capable of eliciting T cell and antibody responses that provide protection against vaginal challenge.

Todd M. Gierahn, T. Gierahn, D. Higgins, 2012, Vaccine.

Identification of Chlamydia trachomatis Antigens Recognized by T Cells From Highly Exposed Women Who Limit or Resist Genital Tract Infection.

T. Darville, S. Hillier, J. Flechtner, 2016, The Journal of infectious diseases.

Therapeutic Vaccine for Genital Herpes Simplex Virus-2 Infection: Findings From a Randomized Trial

D. Bernstein, A. Wald, S. Tasker, 2017, The Journal of infectious diseases.

Identification of novel virus-specific antigens by CD4⁺ and CD8⁺ T cells from asymptomatic HSV-2 seropositive and seronegative donors.

Todd M. Gierahn, D. Long, G. Siber, 2014, Virology.

Evolution of rational vaccine designs for genital herpes immunotherapy.

J. Flechtner, Johanna K. Kaufmann, 2016, Current opinion in virology.

An empirical antigen selection method identifies neoantigens that either elicit broad anti-tumor T cell responses or drive tumor growth.

James J Foti, E. Jaffee, Kwok-Kin Wong, 2021, Cancer discovery.

Improving Cancer Immunotherapies through Empirical Neoantigen Selection.

Catarina Nogueira, Johanna K Kaufmann, Hubert Lam, 2018, Trends in cancer.

248 Empiric profiling of peripheral T cell recall responses to tumor mutanomes versus in silico predictions in NSCLC patients undergoing pembrolizumab treatment ± chemotherapy

A. Visintin, Tulin Dadali, M. Awad, 2021, Journal for ImmunoTherapy of Cancer.

753 InhibigenTM administration promotes aberrant T cell responses in cancer but may be beneficial for amelioration of autoimmune disease

Charley J. Hubbard, H. Lam, J. Flechtner, 2021, Journal for ImmunoTherapy of Cancer.

Abstract LB-223: ATLASTMreveals a dominant inhibitory antigen in melanoma patients, and a reduced breadth of tumor-associated antigen-specific T cells in non-responders to checkpoint blockade

Christopher L. Warren, James J Foti, F. Hodi, 2019, Clinical Research (Excluding Clinical Trials).

Therapeutic HSV-2 vaccine decreases recurrent virus shedding and recurrent genital herpes disease.

D. Bernstein, A. Wald, S. Tasker, 2019, Vaccine.

Systematic analysis of T cell responses specific to the Epstein-Barr virus proteome using ATLAS™

Kevin C. Olivieri, L. Ghamsari, K. Luzuriaga, 2017, The Journal of Immunology.

Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors.

Melissa L. Johnson, R. Cohen, M. Gillison, 2021 .

Development of a high-throughput β-Gal-based neutralization assay for quantitation of herpes simplex virus-neutralizing antibodies in human samples.

D. Long, R. Belshe, L. Morrison, 2016, Vaccine.

A trivalent gC2/gD2/gE2 vaccine for herpes simplex virus generates antibody responses that block immune evasion domains on gC2 better than natural infection.

D. Long, H. Friedman, J. Flechtner, 2019, Vaccine.

Proteins as T cell antigens: methods for high-throughput identification.

D. Higgins, J. Flechtner, D. Grubaugh, 2013, Vaccine.

Development of a high-throughput β-Gal-based neutralization assay for quantitation of herpes simplex virus-neutralizing antibodies in human samples.

Michael P. Cooney, D. Long, R. Belshe, 2016, Vaccine.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.